# EDGAR Filing Document

**Accession Number:** 0001831097
**File Stem:** 0001209191-23-019725
**Filing Date:** 2023-3
**Character Count:** 12832
**Document Hash:** 02fa58b93e251095fcda4937a580506f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-019725.hdr.sgml**: 20230317

**ACCESSION NUMBER**: 0001209191-23-019725

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230315

**FILED AS OF DATE**: 20230317

**DATE AS OF CHANGE**: 20230317

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Shaker Benjamin
- **CENTRAL INDEX KEY:** 0001855843

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40332
- **FILM NUMBER:** 23743493

**MAIL ADDRESS:**
- **STREET 1:** C/O AGILON HEALTH, INC.
- **STREET 2:** 6210 E HWY 290, SUITE 450
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78723
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** agilon health, inc.
- **CENTRAL INDEX KEY:** 0001831097
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **IRS NUMBER:** 371915147
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6210 E HWY 290
- **STREET 2:** SUITE 450
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78723
- **BUSINESS PHONE:** 562-256-3800

**MAIL ADDRESS:**
- **STREET 1:** 6210 E HWY 290
- **STREET 2:** SUITE 450
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78723

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Agilon Health Topco, Inc.
- **DATE OF NAME CHANGE:** 20201103

## Ex-24

```
<PRE>
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints
each of Timothy Bensley, Denise Zamore, Mat Varghese, Steve Meetre and Mimi Yang
and each of them individually, the undersigned's true and lawful
attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as an Officer and/or Director of agilon health, inc. (the "Company"), (i) Forms
3, 4 and 5 and any other forms required to be filed in accordance with Section
16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules
thereunder (a "Section 16 Form"), (ii) a Form ID and any other forms required to
be filed or submitted in accordance with Regulation S-T promulgated by the
United States Securities and Exchange Commission (or any successor provision) in
order to file a Section 16 Form electronically (a "Form ID", and, together with
a Section 16 Form, the "Forms and Schedules") and (iii) notices of proposed
sales of Company securities on Form 144  pursuant to Rule 144 under the
Securities Act of 1933, as amended;

(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Forms and
Schedules, complete and execute any amendment or amendments thereto, and timely
file such Forms and Schedules with the United States Securities and Exchange
Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of each such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by each such attorney-in-fact on behalf
of the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as he or she may approve in his or her
discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that each such attorney-in-fact, or his or
her substitute or substitutes, shall lawfully do or cause to be done by virtue
of this Power of Attorney and the rights and powers herein granted.  The
undersigned acknowledges that each such attorney-in-fact is serving in such
capacity at the request of the undersigned, and is not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file any Forms and Schedules with respect
to the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to each such attorney-in-fact.

From and after the date hereof, any Power of Attorney previously granted by the
undersigned concerning the subject matter hereof is hereby revoked.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of February 22, 2023.

      /s/ Benjamin Shaker
Benjamin Shaker

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Shaker Benjamin<br><sub>(Last) (First) (Middle)</sub><br>C/O AGILON HEALTH, INC.<br>6210 E HWY 290, SUITE 450<br><sub>(Street)</sub><br>AUSTIN, TX 78723<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Markets Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>agilon health, inc. [ AGL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-03-15 |  | M |  | 70000 | A | $1.00 | 95625<sup>(1)</sup> | D |  |
| Common Stock | 2023-03-15 |  | M |  | 25000 | A | $1.00 | 120625<sup>(1)</sup> | D |  |
| Common Stock | 2023-03-15 |  | S |  | 35000 | D | 23.8066<sup>(2)</sup> | 85625<sup>(1)</sup> | D |  |
| Common Stock | 2023-03-15 |  | S<sup>(3)</sup> |  | 25000 | D | 23.803<sup>(4)</sup> | 60625<sup>(1)</sup> | D |  |
| Common Stock | 2023-03-16 |  | M |  | 25000 | A | $1.00 | 85625<sup>(1)</sup> | D |  |
| Common Stock | 2023-03-16 |  | S<sup>(3)</sup> |  | 4588 | D | 24.3551<sup>(5)</sup> | 81037<sup>(1)</sup> | D |  |
| Common Stock | 2023-03-16 |  | S<sup>(3)</sup> |  | 9831 | D | 25.6527<sup>(6)</sup> | 71206<sup>(1)</sup> | D |  |
| Common Stock | 2023-03-16 |  | S<sup>(3)</sup> |  | 10581 | D | 26.0812<sup>(7)</sup> | 60625<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Options (Right to buy) | $1.00 | 2023-03-15 |  | M |  |  | 70000 | <sup>(8)</sup> | 2026-12-30 | Common Stock | 70000 | $0.00 | 257306 | D |  |
| Options (Right to buy) | $1.00 | 2023-03-15 |  | M |  |  | 25000 | <sup>(9)</sup> | 2027-04-27 | Common Stock | 25000 | $0.00 | 26851 | D |  |
| Options (Right to buy) | $1.00 | 2023-03-16 |  | M |  |  | 25000 | <sup>(9)</sup> | 2027-04-27 | Common Stock | 25000 | $0.00 | 1851 | D |  |

---

### Footnotes:

(1) Includes restricted stock units.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.50 to $24.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

(3) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.52 to $24.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

(5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.98 to $24.975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

(6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.98 to $25.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

(7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.98 to $26.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

(8) These options were granted on December 30, 2016, and became fully vested as of January 12, 2021.

(9) These options were granted on April 27, 2017, and became fully vested as of January 12, 2021.

**Remarks:**
Exhibit List:

Ex.24 - Power of Attorney

**Signature:** /s/ Steve Meetre, as Attorney-in-Fact  
**Date:** 2023-03-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**